CES 2026 Samsung Biologics seeks AI-powered manufacturing solutions

Samsung Biologics CEO John Rim browses Samsung Electronics' exhibit at CES 2026 in Las Vegas, Wednesday. Korea Times photo by Kang Seung-woo

LAS VEGAS — Samsung Biologics CEO John Rim attended CES 2026 last week to explore strategies for artificial intelligence (AI)-driven digital transformation in manufacturing.

“Attending CES allows us to experience global trends in advanced technologies and gain insights for manufacturing innovation in the AI era,” Rim said.

He also participated in various sessions during CES, including Caterpillar’s keynote, discussions on AI adoption in manufacturing and automation-based smart factory technologies.

Traditionally a consumer electronics and IT showcase, CES has evolved into a broader platform encompassing AI, robotics, health care and other industries undergoing digital transformation. This year’s edition centered on AI, digital health and advanced mobility, with particular attention on “physical AI” — technologies that enable AI systems to interact directly with the real world.

Nvidia CEO Jensen Huang said, "One of the biggest (and) most important one is physical AI," while global firms such as Siemens and Caterpillar highlighted plans to adopt digital twin and smart factory technologies, emphasizing the critical role of innovation in manufacturing.

Digital manufacturing innovation is accelerating in the pharmaceutical and biotech sectors as well.

Samsung Biologics has advanced its manufacturing execution system and quality execution system to provide customized services for global clients. Its recently commissioned Plant 5 employs AI and digital twin technologies to automate processes, optimize quality management and improve productivity. Electronic manufacturing records and autonomous mobile robots further ensure data integrity and minimize process errors.

Following CES, Rim will attend the JP Morgan Healthcare Conference in San Francisco from Monday through Thursday (local time), where he is set to present Samsung Biologics’ digital transformation strategy and long-term vision.

Building on last year’s engagements, Rim will also meet with top executives and investors to expand the company’s global network and strengthen its corporate credibility.